Does BENDAMUSTINE Cause Plasma cell myeloma refractory? 33 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Plasma cell myeloma refractory have been filed in association with BENDAMUSTINE (VIVIMUSTA). This represents 0.2% of all adverse event reports for BENDAMUSTINE.
33
Reports of Plasma cell myeloma refractory with BENDAMUSTINE
0.2%
of all BENDAMUSTINE reports
9
Deaths
8
Hospitalizations
How Dangerous Is Plasma cell myeloma refractory From BENDAMUSTINE?
Of the 33 reports, 9 (27.3%) resulted in death, 8 (24.2%) required hospitalization, and 4 (12.1%) were considered life-threatening.
Is Plasma cell myeloma refractory Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BENDAMUSTINE. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does BENDAMUSTINE Cause?
Off label use (2,578)
Disease progression (2,456)
Pyrexia (1,322)
Neutropenia (1,256)
Drug ineffective (1,135)
Febrile neutropenia (1,005)
Pneumonia (975)
Thrombocytopenia (967)
Covid-19 (892)
Anaemia (817)
What Other Drugs Cause Plasma cell myeloma refractory?
BORTEZOMIB (618)
DEXAMETHASONE (513)
LENALIDOMIDE (489)
DARATUMUMAB (404)
CARFILZOMIB (386)
POMALIDOMIDE (280)
CYCLOPHOSPHAMIDE (237)
IXAZOMIB (132)
DOXORUBICIN (115)
ETOPOSIDE (90)
Which BENDAMUSTINE Alternatives Have Lower Plasma cell myeloma refractory Risk?
BENDAMUSTINE vs BENDROFLUMETHIAZIDE
BENDAMUSTINE vs BENIDIPINE
BENDAMUSTINE vs BENLYSTA
BENDAMUSTINE vs BENRALIZUMAB
BENDAMUSTINE vs BENSERAZIDE